Company Filing History:
Years Active: 2017
Title: Mark E Webster: Innovator in SGLT2 Inhibitor Development
Introduction
Mark E Webster is a notable inventor based in New York, NY (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of sodium-glucose transporter 2 (SGLT2) inhibitors. His work is crucial in advancing treatments for various medical conditions.
Latest Patents
Mark E Webster holds 1 patent for his invention titled "Methods for preparing SGLT2 inhibitors." This patent relates to innovative methods for preparing a sodium-glucose transporter 2 (SGLT2) inhibitor, a cocrystalline SGLT2, and (S)-5-oxopyrrolidine-2-carboxylic acid (L-PGA) complex, along with intermediates useful in the preparation of the said SGLT2 inhibitor.
Career Highlights
Mark E Webster is currently associated with MSD International GmbH, where he continues to contribute to pharmaceutical innovations. His expertise in the field has positioned him as a valuable asset to his organization.
Collaborations
Throughout his career, Mark has collaborated with notable professionals, including Steven J Brenek and Stephane Caron. These collaborations have further enhanced the impact of his work in the pharmaceutical industry.
Conclusion
Mark E Webster's contributions to the development of SGLT2 inhibitors exemplify his commitment to advancing medical science. His innovative methods and collaborations continue to influence the pharmaceutical landscape.